Close Menu

NEW YORK - Swiss firm Novigenix said today that it is collaborating with radiopharmaceutical company RadioMedix to develop a precision oncology diagnostic for patients with neuroendocrine tumors. 

Under the agreement, Novigenix will create an immune-transcriptomic-based test using its proprietary LITOseek platform to monitor the effectiveness of a type of treatment, alpha and beta peptide receptor radionuclide therapy (PRRT), which RadioMedix is developing.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The New York Times looks at companies using genomic tools to try to quickly identify the cause of patients' infections.

The White House has asked for $2.5 billion in funding to address the COVID-19 outbreak, according to the Associated Press.

A resignation at the Marine Biological Laboratory highlights that institutions are unsure of how to handle researchers previously found to have violated codes of conduct, Nature News says.

In PNAS this week: immune responses that affect heart transplant rejection risk, gene variants associated with thiopurine toxicity, and more.